CBB...
I hope you are wrong as well. I still believe this drug Vascepa is a wonder drug and its story is not fully written. In my view I believe it’s worth a ton of money. If someone with special powers told me that in the not so distant future Amarin will be sitting at a $50-75 dollar share price (because of Vascepa sales), I would just sit tight and shut up. However, this has not yet occurred. It isn’t easy for a one drug company to make it in this current health care world. Especially if they have plans to sell it around the world.
Amarin has been around since 1989. It was more official in 1993. There really hasn’t been much if anything regarding a pipeline, only Vascepa. What company looking to build a drug franchise sticks with only one product? Certainly they would have added to the pipeline to mitigate risk and to add to the future. That speaks volumes to me. In my opinion, I think the GIA plan is in place in the event a deal doesn’t happen. It makes sense. No CEO in their right mind would plan for a sale and not have a backup plan if plan A fails.
I still say something is in the works. I don’t know what the holdup is though. I figured big pharma would have wanted to do this from the beginning (Europe). Yet, what do I know. Perhaps there is much to work out? Perhaps it’s a wait and see thing with regard to current court cases. Who knows...
News 
Market Data 
Discover 
